Evaluation of the MAGLUMI non-competitive angiotensin I chemiluminescence immunoassay for measuring renin activity in human plasma
-
Lina Wu
,
Li Zhang
und
Xiaosong Qin
Abstract
Objectives
Plasma renin activity (PRA) measures the rate of renin converting angiotensinogen to angiotensin I in circulation and reflects the function of renin-angiotensin-aldosterone system (RAAS). The study aimed to demonstrate the performance of the MAGLUMI Angiotensin I assay for the measurement of PRA.
Methods
The MAGLUMI Angiotensin I assay was evaluated for precision, linearity, limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), interferences, cross-reactivity and reference intervals. It was compared to liquid chromatography tandem mass spectrometry (LC-MS/MS) using 54 samples, and impact of clinical factors was assessed in 181 samples.
Results
The assay demonstrated repeatability of 1.5 %, 1.85%, and 1.6 % across three different pool concentrations, with corresponding within-laboratory imprecision values of 2.0 %, 2.5%, and 1.9 %. The linear range was [0.10, 24.0] ng/mL. The LoB, the LoD, and the LoQ were 0.03 ng/mL, 0.07 ng/mL, and 0.10 ng/mL, respectively. The interferences and cross-reactivity met the criterion for acceptable cross-reactivity (CR) with <±10 %. Reference interval validation shows <10 % of a total of 40 healthy individuals’ plasma samples falling outside the established interval for standing and lying position. The MAGLUMI assay showed excellent agreement with LC-MS/MS for both angiotensin I (slope=1.076, intercept=0.109 ng/mL/h, r=0.987, p<0.001) and plasma renin activity (slope=1.131, intercept=−0.386 ng/mL/h, r=0.973, p<0.001).
Conclusions
The MAGLUMI Angiotensin I chemiluminescence immunoassay is a sensitive and reliable commercial kit for detecting plasma renin activity. The assay exhibited robust analytical performance and strong agreement with LC-MS/MS.
-
Research ethics: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committees of Shengjing Hospital of China Medical University (2023PS180) and Pingshan People’s Hospital (SJ-2023-01-01).
-
Informed consent: Informed consent was obtained from all individuals included in this study, or their legal guardians or wards.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Use of Large Language Models, AI and Machine Learning Tools: None declared.
-
Conflict of interest: The authors state no conflict of interest.
-
Research funding: None declared.
-
Data availability: The raw data can be obtained on request from the corresponding author.
References
1. Skeggs, LTJ, Kahn, JR, Shumway, NP. The preparation and function of the hypertensin-converting enzyme. J Exp Med 1956;103:295–9. https://doi.org/10.1084/jem.103.3.295.Suche in Google Scholar PubMed PubMed Central
2. Fountain, JH, Kaur, J, Lappin, SL. Physiology, renin angiotensin system. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.Suche in Google Scholar
3. Norwood, VF, Fernandez, LG, Tufro, A, Gomez, RA (2004). Chapter 128 – development of the renin-angiotensin system. In: Polin, RA, Fox, WW, Abman, SH, editors. Fetal and neonatal physiology, 3rd ed. W.B. Saunders; 2004:1249–56 pp.10.1016/B978-0-7216-9654-6.50131-4Suche in Google Scholar
4. Carretero, OA, Oparil, S. Essential hypertension. Part I: definition and etiology. Circulation 2000;101:329–35. https://doi.org/10.1161/01.cir.101.3.329.Suche in Google Scholar PubMed
5. Mulatero, P, Verhovez, A, Morello, F, Veglio, F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol 2007;67:324–34. https://doi.org/10.1111/j.1365-2265.2007.02898.x.Suche in Google Scholar PubMed
6. Gunnells, JCJ, McGuffin, WLJ, Johnsrude, I, Robinson, RR. Peripheral and renal venous plasma renin activity in hypertension. Ann Intern Med 1969;71:555–75. https://doi.org/10.7326/0003-4819-71-3-555.Suche in Google Scholar PubMed
7. Nair, R, Vaqar, S, StatPearls [Internet]. Renovascular Hypertension. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551587/ [Accessed 22 May 2023].Suche in Google Scholar
8. Adler, GK, Stowasser, M, Correa, RR, Khan, N, Kline, G, McGowan, MJ, et al.. Primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2025;110:2453–95. https://doi.org/10.1210/clinem/dgaf284.Suche in Google Scholar PubMed
9. Rossi, GP, Rossi, FB, Guarnieri, C, Rossitto, G, Seccia, TM. Clinical management of primary aldosteronism: an update. Hypertension 2024;81:1845–56. https://doi.org/10.1161/HYPERTENSIONAHA.124.22642.Suche in Google Scholar PubMed
10. Ha, J, Park, JH, Kim, KJ, Jung, KY, Lee, J, Choi, JH, et al.. Korean endocrine society consensus guidelines for the diagnosis and management of primary aldosteronism. Endocrinol Metab (Seoul) 2023;38:597–618. https://doi.org/10.3803/EnM.2023.1789.Suche in Google Scholar PubMed PubMed Central
11. Jones, DW, Ferdinand, KC, Taler, SJ, Johnson, HM, Shimbo, D, Abdalla, M, et al., Writing Committee Members*. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025;82:e212-316. https://doi.org/10.1161/HYP.0000000000000249.Suche in Google Scholar PubMed
12. Cohen, EL, Conn, JW, Rovner, DR. Postural augmentation of plasma renin activity and aldosterone excretion in normal people. J Clin Investig 1967;46:418–28. https://doi.org/10.1172/JCI105543.Suche in Google Scholar PubMed PubMed Central
13. Lamarre-Cliche, M, de Champlain, J, Lacourcière, Y, Poirier, L, Karas, M, Larochelle, P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005;18:56–64. https://doi.org/10.1016/j.amjhyper.2004.08.025.Suche in Google Scholar PubMed
14. Ohashi, N, Isobe, S, Ishigaki, S, Yasuda, H. Circadian rhythm of blood pressure and the renin-angiotensin system in the kidney. Hypertens Res 2017;40:413–22. https://doi.org/10.1038/hr.2016.166.Suche in Google Scholar PubMed
15. Judge, C, O’Donnell, M. Low sodium intake increases plasma renin activity. eClinicalMedicine 2021;33:100803. https://doi.org/10.1016/j.eclinm.2021.100803.Suche in Google Scholar PubMed PubMed Central
16. Baffour-Awuah, B, Man, M, Goessler, KF, Cornelissen, VA, Dieberg, G, Smart, NA, et al.. Effect of exercise training on the renin-angiotensin-aldosterone system: a meta-analysis. J Hum Hypertens 2024;38:89–101. https://doi.org/10.1038/s41371-023-00872-4.Suche in Google Scholar PubMed PubMed Central
17. O’Donnell, E, Floras, JS, Harvey, PJ. Estrogen status and the renin angiotensin aldosterone system. Am J Physiol Regul Integr Comp Physiol 2014;307:R498–500. https://doi.org/10.1152/ajpregu.00182.2014.Suche in Google Scholar PubMed
18. Cagnoni, F, Njwe, CA, Zaninelli, A, Ricci, AR, Daffra, A, D’Ospina, A, et al.. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag 2010;6:549–59. Published 2010 Aug 9. https://doi.org/10.2147/vhrm.s11816.Suche in Google Scholar PubMed PubMed Central
19. Nehme, A, Zibara, K. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection? Hypertens Res 2017;40:903–9. https://doi.org/10.1038/hr.2017.65.Suche in Google Scholar PubMed
20. Liu, Z, Jin, L, Zhou, W, Zhang, C. The spectrum of plasma renin activity and hypertension diseases: utility, outlook, and suggestions. J Clin Lab Anal 2022;36:e24738. https://doi.org/10.1002/jcla.24738.Suche in Google Scholar PubMed PubMed Central
21. Hartman, D, Sagnella, GA, Chesters, CA, Macgregor, GA. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004;50:2159–61. https://doi.org/10.1373/clinchem.2004.033654.Suche in Google Scholar PubMed
22. Lash, B, Fleischer, N. Radioimmunoassay of angiotensin I, for estimation of plasma renin activity. Clin Chem 1974;20:620–3. https://doi.org/10.1093/clinchem/20.5.620.Suche in Google Scholar
23. Sealey, JE, Laragh, JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med 1975;5:189–202. https://doi.org/10.1016/s0001-2998(75)80033-x.Suche in Google Scholar PubMed
24. Rehan, M, Raizman, JE, Cavalier, E, Don-Wauchope, AC, Holmes, DT. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem 2015;48:377–87. https://doi.org/10.1016/j.clinbiochem.2015.01.003.Suche in Google Scholar PubMed
25. Scharpé, S, Verkerk, R, Sasmito, E, Theeuws, M. Enzyme immunoassay of angiotensin I and renin. Clin Chem 1987;33:1774–7. https://doi.org/10.1093/clinchem/33.10.1774.Suche in Google Scholar
26. Alderman, MH, Cohen, HW, Sealey, JE, Laragh, JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004;17:1–7. https://doi.org/10.1016/j.amjhyper.2003.08.015.Suche in Google Scholar PubMed
27. Carter, S, Owen, LJ, Kerstens, MN, Dullaart, RP, Keevil, BG. A liquid chromatography tandem mass spectrometry assay for plasma renin activity using online solid-phase extraction. Ann Clin Biochem 2012;49:570–9. https://doi.org/10.1258/acb.2012.011186.Suche in Google Scholar PubMed
28. Goldstein, DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983;5:86–99. https://doi.org/10.1161/01.hyp.5.1.86.Suche in Google Scholar PubMed
29. Bauer, JH. Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging 1993;3:238–45. https://doi.org/10.2165/00002512-199303030-00005.Suche in Google Scholar PubMed
30. Valensi, P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol 2021;20:170. Published 2021 Aug 19. https://doi.org/10.1186/s12933-021-01356-w.Suche in Google Scholar PubMed PubMed Central
31. Deary, AJ, Schumann, AL, Murfet, H, Haydock, SF, Foo, RS, Brown, MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002;20:771–7. https://doi.org/10.1097/00004872-200204000-00037.Suche in Google Scholar PubMed
32. Dickerson, JE, Hingorani, AD, Ashby, MJ, Palmer, CR, Brown, MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008–13. https://doi.org/10.1016/s0140-6736(98)07614-4.Suche in Google Scholar PubMed
33. Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence (NICE).2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK547161/.Suche in Google Scholar
Supplementary Material
This article contains supplementary material (https://doi.org/10.1515/cclm-2025-1361).
© 2025 Walter de Gruyter GmbH, Berlin/Boston
